Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Two years of extended anastrozole therapy as effective as five

SABCS 2017

Published: 7 Dec 2017

Views: 2083

Rating:

Save

Prof Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

Prof Gnant speaks at a SABCS 2017 press session about data from the ABCSG-16 phase III trial.

Postmenopausal women with hormone-receptor positive (HR-positive) breast cancer who took the aromatase inhibitor anastrozole for two years after an initial five years of adjuvant endocrine therapy received an equal benefit to those who took the drug for five additional years.

The trial results suggest that a shorter duration of treatment may provide sufficient benefits while protecting women from harmful side effects.

Read the news story for more.

Related Videos

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran

Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

The added value of integrative medicine

Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos

The added value of integrative medicine ( Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

GIST tumours and soft tissue sarcomas

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA

GIST tumours and soft tissue sarcomas ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

More from ecancer